The great Msb short unwind, page-75

MAP levels ≥0.291 were present in 48% of remestemcel-L treated children (12/25) and 37% of the
MAGIC cohort (10/27). Treatment with remestemcel-L resulted in 67% Day 28 Overall Response and
64% Day 180 overall survival compared with 10% Day 28 Overall Response and 10% Day 180
survival in the MAGIC cohort (both p=0.01) when treated with various biologics, including ruxolitinib.


Not only is that a better result than the initial topline data reveals..... It also shows that 48% of MSB trial were in this expected 90% mortality group, whereas only 37% of the Magic controls had the disease to that level of severity.
Meaning if the control group were actually matched based on this expected disease severity Magic score..... then the mortality benefit and the P values would have been even higher yet, and far exceed the primary end point higher than they did already...